Attorney Docket No. 1777.1001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Appl	ication of:							
Takashi SHUTO et al.								
Application No.:	10/765,209	Group Art Unit: 1763						
Filed: January 2	3, 2004	Examiner: Not Yet Assigned						
For: METHOD OF MANUFACTURING CIRCUIT BOARD								
INFORMATION DISCLOSURE STATEMENT								
Commissioner fo PO Box 1450 Alexandria, VA 2								
Sir:								
In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.								
1. Enclosure	Enclosures accompanying this Information Disclosure Statement are:							
1a. ⊠ 1b. ⊠ 1c. ☐ 1d. ☐	Copy(ies) of IDS citation(s), exapplication publications. English language copy of a coor a PCT International Search English language translation (attached to non-English language	compt for U.S. Patents and U.S. Patent mmunication(s) from a foreign Patent Office Report. complete, Abstract or relevant portion(s)) age publications as indicated on the attached						
1e. 1f. 1g.	providing a concise explanation List of Copending Applications	References (ATTACHMENT 1(e), hereto) for in of non-English publications. (ATTACHMENT 1(f), hereto). couments (ATTACHMENT 1(g), hereto).						
2. This Inf	formation Disclosure Statement is (Check either Item 2							
2a.	Within three months of the dat § 1.491 in an international app Before the mailing of a first Of	fice Action on the merits; or						
2d.	Continued Examination under	fice Action after the filing of a Request for § 1.114.						

3. 🛛	This Information Disclosure Statement is filed under 37 CFR § 1.97(c) after the period specified in paragraph 2 above but before the mailing date of any of a Final Office Action under § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise closes prosecution in the application, AND (Check either Item 3a or 3b, Item 3b to be checked if any reference known for more than 3 months)						
	3a. ☐ The § 1.97(e) Statement in Item 5 below is applicable; OR The \$1.97(e) Statement in 37 CFR § 1.17(p) is: enclosed.						
	to be charged to Deposit Account No. 19-3935.						
4.	This Information Disclosure Statement is filed under 37 CFR § 1.97(d) after the period specified in paragraph 3 above, but on or before payment of the Issue Fee, AND						
	4a.						
	to be charged to Deposit Account No. 19-3935.						
5.	Statement under § 1.97(e) (applicable if Item 3a or Item 4a is checked)						
	(Check either Item 5a or 5b)						
	5a. In accordance with 37 CFR § 1.97(e/1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.						
	5b. In accordance with 37 CFR § 197(e)(Z), it is stated that no Item of information contained in this information biosidosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this information Disclosure Statement.						
6.	This is a continuation/divisional/continuation-in-part application under 37 CFR § 1.53(b).						
	(Check appropriate Items 6a and/or 6b)						
	6a. Copies of the publications listed on the attached Form PTO-1449 which were previously ofted in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 196(d).						
	6b. Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.						

Serial No.: 10/765,209

7.	☐ This	is a Request for Continued Examination under 37 CFR § 1.114.
		(Check either Item 7a or 7b)
	7a.	
	7b.	
		concurrently herewith or has been granted. A Request for Continued
		Examination under 37 CFR § 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.
		proper in accordance with 57 CPR § 1.114(a), respectively.
8.	☐ This	is a Supplemental Information Disclosure Statement.
		(Check either Item 8a or 8b)
	8a.	1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can
	O.	be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within
	8b.	one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed
9.		ordance with 37 CFR § 1.98, a concise explanation of what is presently
	unders	stood to be the relevance of each non-English language publication is:
		(Check appropriate Items 9a, 9b, 9c and/or 9d)
	9a.	☐ satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev 2)
	9b.	
	9c.	satisfied for the non-English language publication(s) indicated on the
		attached Form PTO-1449 as having an English language translation
		(complete or relevant portion(s)) attached thereto.
	9d.	enclosed as Attachment 1(e), hereto.
10.	be, ma than se	nission is made that the information cited in this Statement is, or is considered to terial to patentability nor a representation that a search has been made (other earch report(s) from a counterpart foreign application or a PCT International
	Search	Report, if submitted herewith). 37 CFR §§ 1.97(g) and (h).

4

 The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Dated: <u>July 10, 2006</u> 1201 New York Ave., N.W., 7th Floor Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501 By: ____/J, Randall Beckers/ J. Randall Beckers Registration No. 30,358

								1 of _1	
FORM PTO-1-	149	U.S. DI	EPARTMEN [®]	T OF COMMERCE	ATTORNEY DOCKET NO		APPLICA	APPLICATION NO	
		PATENT AND TRADEMARK OFFICE			1777.1001		10/76	10/765,209	
INFOR	MATI	ON DISCLOS	SURE ST	TATEMENT	Takashi Sh				
(Use several sheets if necessary)			- 4	FILING DATE		GROUP/	1763		
(Use several sheets		it necessa	it necessary)		January 28, 2004				
			U.S. P	ATENT DOCUME	NTS				
*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME		CLASS	SUB- CLASS	FILING DATE	
	AA								
	AB								
	AC								
	AD								

FOREIGN PATENT DOCUMENTS DOCUMENT ABSTRACT NO. DATE COUNTRY TRANSLATION YES NO AG WO 96/18284 6/1996 WIPO AH ΑI AJ AK AL

AE

				YES	NO
		AM			
E	XAMINER		DATE CONSIDERED		

TRANSLATION

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.